|
| 37767674 | Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. | JACC Heart Fail | 2024 |
| 37952176 | Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. | JAMA Cardiol | 2024 |
| 37950744 | Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Cardiol | 2024 |
| 38049025 | New Clinical Challenges for Health Providers in the Prescription of Statins in the Elderly. | Am J Med | 2024 |
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37632711 | Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37632455 | Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. | Circulation | 2023 |
| 37857523 | Feasibility of frailty screening among patients with advanced heart failure. | BMJ Open Qual | 2023 |
| 37662283 | Natural Language Processing for Adjudication of Heart Failure Hospitalizations in a Multi-Center Clinical Trial. | medRxiv | 2023 |
| 37793737 | As We Embark on a Second Year. | JACC Heart Fail | 2023 |
| 37886880 | Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. | Circ Heart Fail | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37830208 | Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. | Circulation | 2023 |
| 37771274 | Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37771260 | Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 37220823 | Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial. | J Card Fail | 2023 |
| 37220822 | Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER. | Am Heart J | 2023 |
| 37220172 | Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. | Eur Heart J | 2023 |
| 37220093 | Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. | Eur Heart J | 2023 |
| 37191207 | Incremental prognostic value of biomarkers in PARADIGM-HF. | Eur J Heart Fail | 2023 |
| 37191081 | Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial. | Eur J Heart Fail | 2023 |
| 37350280 | Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation. | Circ Heart Fail | 2023 |
| 37019557 | Centrally Adjudicated Heart Failure Outcomes Are Needed in Clinical Trials. | JACC Heart Fail | 2023 |
| 37286262 | Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides. | JACC Heart Fail | 2023 |
| 37051752 | Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. | Eur Heart J | 2023 |
| 37212758 | Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. | J Am Coll Cardiol | 2023 |
| 37212168 | Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37211977 | Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. | Eur J Heart Fail | 2023 |
| 37210743 | Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. | Eur Heart J | 2023 |
| 37210608 | Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. | Eur J Heart Fail | 2023 |
| 36944496 | Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. | Eur Heart J | 2023 |
| 36943907 | Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. | Circ Heart Fail | 2023 |
| 37208998 | Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37407154 | Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan. | JACC Heart Fail | 2023 |
| 37407155 | Optimizing Background Therapy for Heart Failure in Clinical Trials: Towards a More Objective Approach. | JACC Heart Fail | 2023 |
| 37140514 | How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians. | JACC Heart Fail | 2023 |
| 37467498 | Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. | N Engl J Med | 2023 |
| 37369637 | Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. | Eur J Heart Fail | 2023 |
| 37401511 | Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 37366061 | Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? | Circulation | 2023 |
| 37230649 | Valvular Regurgitation in Adults with Congenital Heart Disease and Heart Failure: Current Status and Potential Interventions. | Heart Fail Clin | 2023 |
| 37099283 | Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37358785 | Stroke in patients with heart failure and reduced or preserved ejection fraction. | Eur Heart J | 2023 |
| 37294244 | Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. | JACC Heart Fail | 2023 |
| 37226448 | Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. | JACC Heart Fail | 2023 |
| 37226447 | Life-Prolonging Benefits of LVAD Therapy in Advanced Heart Failure: A Clinician's Action and Communication Aid. | JACC Heart Fail | 2023 |
| 37062869 | Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE. | Eur J Heart Fail | 2023 |
| 36889870 | Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. | J Am Coll Cardiol | 2023 |
| 36477809 | Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. | JAMA Cardiol | 2023 |